Human peripheral blood mononuclear cell substrate for propagating wild type HIV-1.

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Molecularly derived HIV proteins have historically failed to elicit broadly neutralizing antibodies (NAB) and cytotoxic T cell (CTL) responses essential for effective HIV vaccination.
• Natural virion proteins from primary HIV-1 isolates offer a potential alternative for vaccine development.

Purpose of the Study:

• To develop a novel polyvalent HIV vaccine (HIVAX) using natural virion proteins from primary HIV-1 isolates.
• To induce both HIV-NAB and CTL responses, considered critical for an effective HIV vaccine.

Main Methods:

• Utilizing human peripheral blood mononuclear cells (PBMC) to grow primary HIV-1 isolates.
• Employing viral inactivation techniques including chemical (DMMB, EDI, psoralens) and physical (hydrostatic pressure cycling, flash pasteurization) methods.
• Pooling diverse HIV isolates (Subtypes B, C, A, D, E, 'X') and quantifying key antigens (gp120, gp41, p24, p31) for vaccine consistency.

Main Results:

• The proposed HIVAX vaccine strategy aims to generate a polyvalent preparation reflecting antigenic diversity.
• Safety is assessed through RT-PCR for nucleic acid amplification and infectivity testing in animal models.
• Antigen content (gp120, gp41, p24, p31) is rigorously quantified to ensure product consistency.

Conclusions:

• HIVAX, derived from natural virion proteins, presents a novel strategy for inducing both NAB and CTL responses.
• The vaccine framework leverages proven technologies for safe and efficient production from human blood-derived sources.
• Ultimate efficacy of HIVAX requires validation through human clinical trials in high-risk populations.